美股新聞 標題聯播 · 近 24 小時 336 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · IRD近 30 天 3 則 · 第 1 / 1 頁
- Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?
- Sector Update: Healthcare Stocks Softer Late Afternoon
- Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
- Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
- Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
- Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
- Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
- Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
- Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
- RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup
- Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
- Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
- Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price Target
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。